The TKI crizotinib was the first target drug FDA-approved with multi-kinase activity against MET, ALK, and ROS1 [34,35,36]; however, the best patient response to crizotinib was in ALK-positive NSCLC patients compared to MET and ROS1 positive patients [37]. Here, ALK is linked to non-small cell lung carcinoma.